Published in Mol Endocrinol on January 27, 2005
Mitotic chromosomal instability and cancer: mouse modelling of the human disease. Nat Rev Cancer (2010) 3.95
Acromegaly pathogenesis and treatment. J Clin Invest (2009) 2.19
Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol (2005) 1.40
p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A (2008) 1.31
Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res (2010) 1.24
Isolation of tumour stem-like cells from benign tumours. Br J Cancer (2009) 1.10
Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res (2007) 1.09
Aneuploidy and chromosomal instability in cancer: a jackpot to chaos. Cell Div (2015) 1.07
Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer (2006) 1.07
PTTG: an important target gene for ovarian cancer therapy. J Ovarian Res (2008) 1.01
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One (2011) 0.95
Growth hormone is a cellular senescence target in pituitary and nonpituitary cells. Proc Natl Acad Sci U S A (2013) 0.93
Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog (2011) 0.92
The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res (2006) 0.92
Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways. Expert Rev Endocrinol Metab (2010) 0.90
Pituitary tumor transforming gene induces epithelial to mesenchymal transition by regulation of Twist, Snail, Slug, and E-cadherin. Cancer Lett (2011) 0.89
E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol (2009) 0.84
Animal models of pituitary neoplasia. Mol Cell Endocrinol (2015) 0.83
Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol (2010) 0.82
PTTG1 attenuates drug-induced cellular senescence. PLoS One (2011) 0.82
Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. Mol Endocrinol (2012) 0.81
Pituitary adenoma growth: a model for cellular senescence and cytokine action. Cell Cycle (2009) 0.80
Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice. BMC Cancer (2012) 0.79
The role of genetic and epigenetic changes in pituitary tumorigenesis. Neurol Med Chir (Tokyo) (2014) 0.78
Securin promotes migration and invasion via matrix metalloproteinases in glioma cells. Oncol Lett (2015) 0.78
Mouse models of endocrine tumours. Best Pract Res Clin Endocrinol Metab (2010) 0.78
Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A (2014) 0.76
mTOR promotes pituitary tumor development through activation of PTTG1. Oncogene (2016) 0.75
Screening of feature genes in distinguishing different types of breast cancer using support vector machine. Onco Targets Ther (2015) 0.75
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Prospective 10-year surveillance of human prion diseases in Japan. Brain (2010) 2.41
Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.01
Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem (2006) 2.00
Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev (2007) 1.79
In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med (2006) 1.52
Angiogenesis in endocrine tumors. Endocr Rev (2003) 1.50
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest (2011) 1.49
Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol (2005) 1.40
Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab (2011) 1.34
p21Cip1 restricts neuronal proliferation in the subgranular zone of the dentate gyrus of the hippocampus. Proc Natl Acad Sci U S A (2008) 1.31
p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A (2008) 1.31
Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology (2003) 1.29
Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest (2002) 1.24
Acromegaly. Endocrinol Metab Clin North Am (2008) 1.23
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab (2008) 1.19
Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A (2003) 1.19
PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest (2003) 1.18
Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. J Clin Endocrinol Metab (2004) 1.15
Molecular targets in pituitary tumours. Nat Rev Cancer (2004) 1.14
The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet (2006) 1.14
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med (2002) 1.14
In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells. J Immunol (2008) 1.09
Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res (2007) 1.09
Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol Endocrinol (2003) 1.09
Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary (2013) 1.08
The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab (2008) 1.08
Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest (2004) 1.06
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A (2011) 1.05
Ectopic acromegaly due to growth hormone releasing hormone. Endocrine (2012) 1.05
Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One (2012) 1.05
Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology (2002) 1.04
Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab (2008) 1.03
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology (2006) 1.02
Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One (2011) 1.02
T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury. PLoS One (2008) 0.99
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res (2008) 0.98
Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum Mol Genet (2006) 0.97
Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab (2014) 0.96
Hypothalamic-pituitary cytokine network. Endocrinology (2003) 0.96
Skeletal muscle adaptations to testosterone and resistance training in men with COPD. J Appl Physiol (1985) (2007) 0.95
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One (2011) 0.95
A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest (2012) 0.94
Growth hormone is a cellular senescence target in pituitary and nonpituitary cells. Proc Natl Acad Sci U S A (2013) 0.93
p21Cip restrains hippocampal neurogenesis and protects neuronal progenitors from apoptosis during acute systemic inflammation. Hippocampus (2013) 0.92
Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol (2007) 0.92
Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet (2011) 0.92
Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab (2006) 0.90
Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab (2008) 0.90
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol (2010) 0.90
Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology (2007) 0.89
Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. Mol Endocrinol (2005) 0.89
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab (2006) 0.89
Diminished pancreatic beta-cell mass in securin-null mice is caused by beta-cell apoptosis and senescence. Endocrinology (2009) 0.89
Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer (2010) 0.88
Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One (2011) 0.88
Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab (2012) 0.88
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary (2014) 0.87
Heregulin regulates prolactinoma gene expression. Cancer Res (2009) 0.87
Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab (2008) 0.87
A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling. Endocrinol Nutr (2011) 0.87
Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol (2009) 0.86
Treatment of acromegaly: future. Endocrine (2005) 0.86
Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab (2013) 0.86
The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab (2004) 0.86
Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab (2003) 0.86
Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol (2007) 0.85
Insight into the frequent occurrence of dura mater graft-associated Creutzfeldt-Jakob disease in Japan. J Neurol Neurosurg Psychiatry (2013) 0.85
Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma. J Clin Endocrinol Metab (2009) 0.85
The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion. J Clin Endocrinol Metab (2003) 0.84
Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer (2011) 0.84
Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PLoS One (2010) 0.84
Pituitary tumor transforming gene: an update. Front Horm Res (2004) 0.84
E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors. Mol Endocrinol (2009) 0.84
Sca1⁺ murine pituitary adenoma cells show tumor-growth advantage. Endocr Relat Cancer (2014) 0.83
Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem (2005) 0.83
Supplemental growth hormone in healthy adults: the endocrinologist's responsibility. Nat Clin Pract Endocrinol Metab (2006) 0.83
Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs (2007) 0.83
Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab (2009) 0.83
Graft-related disease progression in dura mater graft-associated Creutzfeldt-Jakob disease: a cross-sectional study. BMJ Open (2013) 0.83